Robert J. Van Gulick

608 total citations
14 papers, 242 citations indexed

About

Robert J. Van Gulick is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Robert J. Van Gulick has authored 14 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Robert J. Van Gulick's work include Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (5 papers) and CAR-T cell therapy research (4 papers). Robert J. Van Gulick is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (5 papers) and CAR-T cell therapy research (4 papers). Robert J. Van Gulick collaborates with scholars based in United States and Netherlands. Robert J. Van Gulick's co-authors include William A. Robinson, Kasey L. Couts, Carol M. Amato, Morgan MacBeth, Richard P. Tobin, Jacqueline A. Turner, Mayumi Fujita, Martin D. McCarter, Stacey M. Bagby and Yiqun G. Shellman and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Robert J. Van Gulick

14 papers receiving 241 citations

Peers

Robert J. Van Gulick

ONCOL

IMMUN

PRM

Kelsey W. Nassar United States

Gavin D. Garland United Kingdom

Thomas Mehrling United Kingdom

Karen Jung Canada

Dang-Nghiem Vo France

Roger Inhorn United States

Lucie Heinzerling Germany

Julia Vaübel Germany

Yee Peng Phoon United States

Rachel A. Woolaver United States

Kelsey W. Nassar United States

Robert J. Van Gulick

164 ×1.3

170 ×1.4

ONCOL

84 ×1.2

IMMUN

35 ×1.2

36 ×1.5

PRM

Citations per year, relative to Robert J. Van Gulick Robert J. Van Gulick (= 1×) peers Kelsey W. Nassar

Countries citing papers authored by Robert J. Van Gulick

Since Specialization

Citations

This map shows the geographic impact of Robert J. Van Gulick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Van Gulick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Van Gulick more than expected).

Fields of papers citing papers by Robert J. Van Gulick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Van Gulick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Van Gulick. The network helps show where Robert J. Van Gulick may publish in the future.

Co-authorship network of co-authors of Robert J. Van Gulick

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Van Gulick. A scholar is included among the top collaborators of Robert J. Van Gulick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Van Gulick. Robert J. Van Gulick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Turner, Jacqueline A., Morgan MacBeth, Robert J. Van Gulick, et al.. (2023). Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity. Nature Communications. 14(1). 3214–3214. 25 indexed citations

Davis, Dana M., Robert J. Van Gulick, Robert J. Torphy, et al.. (2022). Circulating CD8 ⁺ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients. Clinical & Translational Immunology. 11(1). e1367–e1367. 15 indexed citations

Turner, Jacqueline A., Robert J. Van Gulick, Davide Stefanoni, et al.. (2022). BRAF Modulates Lipid Use and Accumulation. Cancers. 14(9). 2110–2110. 7 indexed citations

Aktürk, Halis Kaan, Kasey L. Couts, Erin E. Baschal, et al.. (2022). Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. JAMA Network Open. 5(12). e2246400–e2246400. 25 indexed citations

McCarter, Martin D., Richard P. Tobin, Dana M. Davis, et al.. (2021). Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.. Journal of Clinical Oncology. 39(15_suppl). 9536–9536. 4 indexed citations

MacBeth, Morgan, Robert J. Van Gulick, Richard P. Tobin, et al.. (2021). Targeting the RIG-I-like receptor signaling pathway to improve the efficacy of immunotherapy in mucosal and uveal melanoma.. Journal of Clinical Oncology. 39(15_suppl). e21593–e21593. 1 indexed citations

MacBeth, Morgan, Richard P. Tobin, Robert J. Van Gulick, et al.. (2021). Abstract PO048: Loss of intra-tumoral RIG-I immune signaling is a potential microbiome-mediated mechanism underlying poor anti-tumor immunity and immunotherapy resistance in mucosal melanoma. Cancer Research. 81(5_Supplement). PO048–PO048. 1 indexed citations

Mukherjee, Nabanita, Carol M. Amato, Morgan MacBeth, et al.. (2021). A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. Pharmaceuticals. 14(8). 749–749. 3 indexed citations

Borgers, Jessica S.W., Richard P. Tobin, Robert J. Torphy, et al.. (2021). Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network. 19(13). 53–63. 10 indexed citations

10.

Mukherjee, Nabanita, Carol M. Amato, William A. Robinson, et al.. (2020). Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers. 12(8). 2182–2182. 26 indexed citations

11.

Gulick, Robert J. Van, Carol M. Amato, Morgan MacBeth, et al.. (2020). Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Research. 30(6). 562–573. 24 indexed citations

12.

Mukherjee, Nabanita, William A. Robinson, Carol M. Amato, et al.. (2020). MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death and Disease. 11(6). 443–443. 59 indexed citations

13.

Gorden, Nicholas T., Robert J. Van Gulick, Carol M. Amato, et al.. (2019). Biomarkers to predict immune-related adverse events with checkpoint inhibitors.. Journal of Clinical Oncology. 37(8_suppl). 131–131. 14 indexed citations

14.

Turner, Jacqueline A., Stacey M. Bagby, Anna Capasso, et al.. (2018). BRAF fusions identified in melanomas have variable treatment responses and phenotypes. Oncogene. 38(8). 1296–1308. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact